Hematopoietic CC-Chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and Amyloid pathology in a transgenic mouse model of Alzheimer's disease

Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 297-313

  Naert, Gaëlle ^a   Rivest, Serge ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHEMOKINE RECEPTOR CCR2; PLASMID VECTOR; PRESENILIN 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE MARROW CELL; CCR2 GENE; CELLULAR DISTRIBUTION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; GENE EXPRESSION; GENE LOCATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPETENT CELL; MALE; MARKER GENE; MEMORY CONSOLIDATION; MONOCYTE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STEM CELL GENE THERAPY; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AVOIDANCE LEARNING; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; MALE; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CCR2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84860876124     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00306     Document Type: Article

References (74)

1. Lesne S, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440:352-357.
2. Haass C, Selkoe DJ. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8:101-112.
3. Selkoe DJ. (2002) Alzheimer's disease is a synaptic failure. Science. 298:789-791.
4. Perry VH, Gordon S. (1988) Macrophages and microglia in the nervous system. Trends Neurosci. 11:273-277.
5. Dickson DW, et al. (1988) Alzheimer's disease: a double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132:86-101.
6. Haga S, Akai K, Ishii T. (1989) Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohisto-chemical study using a novel monoclonal antibody. Acta. Neuropathol. 77:569-575.
7. Simard AR, Soulet D, Gowing G, Julien J P, Rivest S. (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 49:489-502.
8. Stalder AK, et al. (2005) Invasion of hematopoi-etic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25:11125-11132.
9. Malm TM, et al. (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 18:134-142.
10. Kaur C, Ling EA, Wong WC. (1987) Origin and fate of neural macrophages in a stab wound of the brain of the young rat. J. Anat. 154:215-227.
11. Ling EA. (1979) Transformation of monocytes into amoeboid microglia in the corpus callosum of postnatal rats, as shown by labelling mono-cytes by carbon particles. J. Anat. 128:847-858.
12. Soulet D, Rivest S. (2008) Bone-marrow-derived microglia: myth or reality? Curr. Opin. Pharmacol. 8:508-518.
13. Geissmann F, Jung S, Littman DR. (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 19:71-82.
14. Auffray C, et al. (2009) CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J. Exp. Med. 206:595-606.
15. Charo IF, Ransohoff RM. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354:610-621.
16. Luster AD. (1998) Chemokines: chemotactic cy-tokines that mediate inflammation. N. Engl. J. Med. 338:436-445.
17. Mack M, et al. (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166:4697-4704.
18. Saederup N, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One. 5:e13693.
19. Si Y, Tsou CL, Croft K, Charo IF. (2010) CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J. Clin. Invest. 120:1192-1203.
20. Engel DR, et al. (2008) CCR2 mediates homeosta-tic and inflammatory release of Gr1(high) mono-cytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection. J. Immunol. 181:5579-5586.
21. Serbina NV, Pamer EG. (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7:311-317.
22. Tsou CL, et al. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117:902-909.
23. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. (2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192:1075-1080.
24. Babcock AA, Kuziel WA, Rivest S, Owens T. (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23:7922-7930.
25. D'Mello C, Le T, Swain MG. (2009) Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neu-rosci. 29:2089-2102.
26. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F. (2003) Chemokine receptors in inflammation: an overview. J. Immunol. Meth. 273:3-13.
27. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. (1990) Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoat-tractant, MCP-1/JE. Am. J. Pathol. 136:1229-1233.
28. Cushing SD, et al. (1990) Minimally modified low density lipoprotein induces monocyte chemotac-tic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 87:5134-5138.
29. Smits HA, et al. (2002) Amyloid-beta-induced chemokine production in primary human macro -phages and astrocytes. J. Neuroimmunol. 127:160-168.
30. Glabinski AR, et al. (1996) Chemokine monocyte chemoattractant protein-1 is expressed by astro-cytes after mechanical injury to the brain. J. Immunol. 156:4363-4368.
31. El Khoury JB, et al. (2003) CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197:1657-1666.
32. Meda L, et al. (1995) Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 374:647-650.
33. Deshmane SL, Kremlev S, Amini S, Sawaya BE. (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29:313-326.
34. Ishizuka K, et al. (1997) Identification of mono-cyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psych. Clin. Neurosci. 51:135-138.
35. Grammas P, Ovase R. (2001) Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging. 22:837-842.
36. El Khoury J, et al. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13:432-438.
37. Naert G, Rivest S. (2011) The role of microglial cell subsets in Alzheimer's disease. Curr. Alzheimer Res. 8:151-155.
38. Simard AR, Rivest S. (2006) Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol. Psychiatry. 11:327-335.
39. Richard KL, Filali M, Prefontaine P, Rivest S. (2008) Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 28:5784-5793.
40. Nadeau S, Rivest S. (2000) Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. J. Neurosci. 20:3456-3468.
41. Laflamme N, Lacroix S, Rivest S. (1999) An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J. Neurosci. 19:10923-10930.
42. Laflamme N, Rivest S. (2001) Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J. 15:155-163.
43. Naert G, Laflamme N, Rivest S. (2009) Toll-like receptor 2-independent and MyD88-dependent gene expression in the mouse brain. J. Innate. Immun. 1:480-493.
44. Paxinos G, Franklin KBJ. (2001) The mouse brain in stereotaxic coordinates. 2nd ed. San Diego: Academic Press. [186 pp].
45. Boissonneault V, et al. (2009) Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain. 132:1078-1092.
46. Lue LF, et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:853-862.
47. McLean CA, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurode-generation in Alzheimer's disease. Ann. Neurol. 46:860-866.
48. Cheng IH, et al. (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282:23818-23828.
49. Jia T, et al. (2008) Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocyto-genes infection. J. Immunol. 180:6846-6853.
50. Lesne S, Kotilinek L, Ashe KH. (2008) Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience. 151:745-749.
51. Cleary JP, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84.
52. Klyubin I, et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28:4231-4237.
53. Hung LW, et al. (2008) Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J. Neurosci. 28:11950-11958.
54. Shankar GM, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14:837-842.
55. Steinerman JR, et al. (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch. Neurol. 65:906-912.
56. Bolmont T, et al. (2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 28:4283-4292.
57. Lee S, et al. (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 177:2549-2562.
58. Liu Z, Condello C, Schain A, Harb R, Grutzendler J. (2010) CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J. Neurosci. 30:17091-17101.
59. Mandrekar S, et al. (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29:4252-4262.
60. Magga J, et al. (2011) Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease. J. Cell. Mol. Med. 2011, Jul 21 [Epub ahead of print].
61. Lebson L, et al. (2010) Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J. Neu-rosci. 30:9651-9658.
62. Mousseau DD, et al. (2003) A direct interaction between transforming growth factor (TGF)-betas and amyloid-beta protein affects fibrillogenesis in a TGF-beta receptor-independent manner. J. Biol. Chem. 278:38715-8722.
63. Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. (2003) Loss of TGF-beta 1 leads to increased neu-ronal cell death and microgliosis in mouse brain. Neuron. 40:1133-1145.
64. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. (2000) Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am. J. Path. 156:139-150.
65. Wyss-Coray T, et al. (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:612-618.
66. Wyss-Coray T, et al. (1997) Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature. 389:603-606.
67. Town T, et al. (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimerlike pathology. Nat. Med. 14:681-687.
68. Deane R, et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43:333-344.
69. Shibata M, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489-1499.
70. Deane R, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9:907-913.
71. DeMattos RB, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850-8855.
72. Lemere CA, et al. (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol. Dis. 14:10-18.
73. Holtzman DM, Bales KR, Paul SM, DeMattos RB. (2002) Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv. Drug Deliv. Rev. 54:1603-1613.
74. Cartier N, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823.